Open AccessIn Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis
Author(s) -
Faith Borgan,
Heikki Laurikainen,
Mattia Veronese,
Tiago Reis Marques,
Merja HaaparantaSolin,
Olof Solin,
Tarik Dahoun,
Maria Rogdaki,
Raimo K. R. Salokangas,
Max Karukivi,
Marta Di Forti,
Federico Turkheimer,
Jarmo Hietala,
Oliver Howes,
for the METSY Group
Publication year - 2019
Publication title -
jama psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.531
H-Index - 365
eISSN - 2168-6238
pISSN - 2168-622X
DOI - 10.1001/jamapsychiatry.2019.1427
Subject(s) - psychosis , cannabinoid , cannabidiol , cannabis , in vivo , cannabinoid receptor , neuroscience , psychology , medicine , psychiatry , receptor , pharmacology , biology , agonist , genetics
Experimental and epidemiological studies implicate the cannabinoid 1 receptor (CB1R) in the pathophysiology of psychosis. However, whether CB1R levels are altered in the early stages of psychosis and whether they are linked to cognitive function or symptom severity remain unknown.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom